CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, cilt.21, sa.4, ss.233-236, 2013 (SCI-Expanded)
Background: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older.